Related products
Product Description
Gilternib 40mg is a targeted medication used for the treatment of acute myeloid leukemia (AML) with a specific genetic mutation called FLT3. It is a tyrosine kinase inhibitor that works by blocking the activity of the FLT3 protein, which is responsible for the growth and division of cancer cells. Taken orally in tablet form, Gilternib is typically prescribed for patients who have relapsed or are refractory to initial chemotherapy treatments. While it offers a new treatment option for FLT3-mutated AML, it may have potential side effects such as nausea, diarrhea, fatigue, and liver function abnormalities. Close monitoring and adherence to healthcare providers’ instructions are crucial for safe and effective use of Gilternib 40mg.
